Primary Hepatic EBV-DLBCL Lymphoma in the Setting of COVID-19 Infection

ACG Case Rep J. 2024 Feb 7;11(2):e01276. doi: 10.14309/crj.0000000000001276. eCollection 2024 Feb.

Abstract

This case study describes an instance of primary hepatic diffuse large B cell lymphoma (DLBCL) in a patient who had prolonged coronavirus disease 2019 (COVID-19). DLBCL rarely presents as a primary hepatic mass. The 53-year-old man sought emergency care because of fatigue and weight loss. Diagnostic tests showed mildly elevated liver enzymes and imaging pointed to several low-density liver lesions. A liver biopsy paired with immunohistochemical testing verified the DLBCL diagnosis. Notably, the patient had COVID-19 4 months before the liver-related symptoms. The link between COVID-19 and the emergence of solid tumor cancers is unclear, but this case underscores its potential significance and the need for further research. This report stresses the importance of recognizing and documenting instances where COVID-19 might influence the onset of solid tumor cancers, including primary hepatic DLBCL.

Keywords: COVID-19; DLBCL; oncogenic features of COVID 19; primary hepatic lymphoma.

Publication types

  • Case Reports